Revaccination with the RSV prefusion F vaccine was immunogenic and well-tolerated among adults, according to findings published in The Journal of Infectious Diseases. Edward E. Walsh, MD, and colleagues examined antibody persistence after initial vaccination and safety and immunogenicity after revaccination among 263 adults (age 18−49: n=134; age 65−85: n=129). At 1 month after initial vaccination, geometric mean fold rises (GMFRs) for both RSV-A and RSV-B subgroups were 13.3−20.4 and 8.9−15.5 for the younger and older age groups, respectively. Corresponding GMFRs 12 months after the initial vaccination were 4.1−5.0 and 2.6−4.1. At 1 month after revaccination, GMFRs were 1.4−2.3 and 1.4−2.2 for those aged 18−49 and those aged 65−85, respectively, compared with levels before revaccination. Peak geometric mean neutralizing titers (GMTs) after revaccination were lower than those following the first vaccine dose. GMTs 12 months after initial vaccination and revaccination were similar, and the researchers reported no safety issues.
